Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation : a meta-analysis
OBJECTIVE: To compare efficacy and safety of basiliximab versus antithymocyte globulin (ATG) for induction therapy in kidney transplantation.
METHODS: A literature search of the MEDLINE, EMBASE, CBMdisc, and Cochrane databases was used to identify randomized controlled trials that compared basiliximab and ATG for induction therapy in kidney transplantation. Inclusion criteria comprised: prospective randomized controlled clinical trials, follow-up time >or=12 months, randomized comparisons of ATG versus basiliximab as induction therapy in kidney transplantation. Meta-analytical techniques were applied to identify differences in outcomes between the two agents.
RESULTS: A total of six studies involving 853 patients were identified. No differences between ATG and basiliximab were seen in terms of biopsy-proven rejection (relative risk [RR] 1.15, 95% confidence interval [CI] 0.88-1.52, P = .31), delayed graft function (RR 1.02, 95% CI 0.69-1.51, P = .93), graft loss (RR 1.15, 95% CI 0.73-1.80, P = .55), and patient death (RR 1.22, 95% CI 0.65-2.30, P = .54). But basiliximab had a lower incidence of infection (RR 0.87, 95% CI 0.78-0.97, P = .02) and neoplasm (RR 0.29, 95% CI 0.09-0.97, P = .04).
CONCLUSIONS: Basiliximab is as effective as ATG for induction therapy in kidney transplantation, whereas basiliximab has a lower incidence of infection. Basiliximab may be a safer and preferable option for induction therapy in kidney transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Transplantation proceedings - 42(2010), 5 vom: 19. Juni, Seite 1667-70 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9927MT646M |
|---|
| Anmerkungen: |
Date Completed 29.10.2010 Date Revised 10.12.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.transproceed.2010.02.088 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM199481601 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM199481601 | ||
| 003 | DE-627 | ||
| 005 | 20231223214742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transproceed.2010.02.088 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0665.xml |
| 035 | |a (DE-627)NLM199481601 | ||
| 035 | |a (NLM)20620496 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation |b a meta-analysis |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.2010 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To compare efficacy and safety of basiliximab versus antithymocyte globulin (ATG) for induction therapy in kidney transplantation | ||
| 520 | |a METHODS: A literature search of the MEDLINE, EMBASE, CBMdisc, and Cochrane databases was used to identify randomized controlled trials that compared basiliximab and ATG for induction therapy in kidney transplantation. Inclusion criteria comprised: prospective randomized controlled clinical trials, follow-up time >or=12 months, randomized comparisons of ATG versus basiliximab as induction therapy in kidney transplantation. Meta-analytical techniques were applied to identify differences in outcomes between the two agents | ||
| 520 | |a RESULTS: A total of six studies involving 853 patients were identified. No differences between ATG and basiliximab were seen in terms of biopsy-proven rejection (relative risk [RR] 1.15, 95% confidence interval [CI] 0.88-1.52, P = .31), delayed graft function (RR 1.02, 95% CI 0.69-1.51, P = .93), graft loss (RR 1.15, 95% CI 0.73-1.80, P = .55), and patient death (RR 1.22, 95% CI 0.65-2.30, P = .54). But basiliximab had a lower incidence of infection (RR 0.87, 95% CI 0.78-0.97, P = .02) and neoplasm (RR 0.29, 95% CI 0.09-0.97, P = .04) | ||
| 520 | |a CONCLUSIONS: Basiliximab is as effective as ATG for induction therapy in kidney transplantation, whereas basiliximab has a lower incidence of infection. Basiliximab may be a safer and preferable option for induction therapy in kidney transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antilymphocyte Serum |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a Basiliximab |2 NLM | |
| 650 | 7 | |a 9927MT646M |2 NLM | |
| 700 | 1 | |a Zhou, P |e verfasserin |4 aut | |
| 700 | 1 | |a Han, M |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, C-B |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, X-P |e verfasserin |4 aut | |
| 700 | 1 | |a Li, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation proceedings |d 1969 |g 42(2010), 5 vom: 19. Juni, Seite 1667-70 |w (DE-627)NLM000011029 |x 1873-2623 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2010 |g number:5 |g day:19 |g month:06 |g pages:1667-70 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.transproceed.2010.02.088 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2010 |e 5 |b 19 |c 06 |h 1667-70 | ||